Top

Published in:

Open Access 01-11-2018 | Original Contributions

Discrepancies Between BMI and Classic Cardiovascular Risk Factors

Authors: Stefanie R. van Mil, Guy H. E. J. Vijgen, Astrid van Huisstede, Boudewijn Klop, Gert-Jan M. van de Geijn, Erwin Birnie, Gert-Jan Braunstahl, Guido H. H. Mannaerts, L. Ulas Biter, Manuel Castro Cabezas

Published in: Obesity Surgery | Issue 11/2018

Abstract

Background

Obesity is related to increased cardiovascular risk. It is unknown whether increasing levels of obesity also increase levels of cardiovascular risk factors and systemic inflammation. This study describes the relationship between classic cardiovascular risk factors and inflammatory markers with BMI in a group of obese and non-obese subjects.

Materials and Methods

Obese subjects (BMI ≥ 30 kg/m²; n = 576; mean ± SD BMI 43.8 ± 7.58 kg/m²) scheduled for bariatric surgery were included. The reference population consisted of non-obese volunteers (BMI < 30 kg/m²; n = 377, BMI 25.0 ± 2.81 kg/m²). The relationship between BMI quintiles and the levels of cardiovascular risk factors was analyzed. Adipose tissue volumetry was performed in 42 obese subjects using abdominal CT scans.

Results

The obese group included more women and subjects with type 2 diabetes mellitus, hypertension, and current smoking behavior. In obese subjects, HDL-C and triglycerides decreased with increasing BMI. Systolic and diastolic blood pressure, total cholesterol, LDL-C, and apoB were not related to BMI in the obese group, in contrast to the non-obese group. Inflammatory markers CRP, leukocyte count, and serum complement C3 increased with increasing BMI in the obese group, while these relations were less clear in the non-obese group. The subcutaneous adipose tissue surface was positively correlated to BMI, while no correlation was observed between BMI and visceral adipose tissue.

Conclusions

Markers of inflammation are strongest related to BMI in obese subjects, most likely due to increased adipose tissue mass, while cardiovascular risk factors do not seem to deteriorate above a certain BMI level. Limited expansion capacity of visceral adipose tissue may explain these findings.

Nguyen NT, Magno CP, Lane KT, et al. Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the National Health and Nutrition Examination Survey, 1999 to 2004. J Am Coll Surg. 2008;207(6):928–34. https://doi.org/10.1016/j.jamcollsurg.2008.08.022.CrossRefPubMed

Prospective Studies Collaboration. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373(9669):1083–96. https://doi.org/10.1016/S0140-6736(09)60318-4.CrossRefPubMedCentral

McTigue K, Larson JC, Valoski A, et al. Mortality and cardiac and vascular outcomes in extremely obese women. JAMA. 2006;296(1):79–86.CrossRefPubMed

Flegal KM, Kit BK, Orpana H, et al. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA. 2013;309(1):71–82. Available from: http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=23280227&retmode=ref&cmd=prlinks%5Cnpapers3://publication/doi/10.1001/jama.2012.113905 CrossRefPubMedPubMedCentral

Wormser D, Kaptoge S, Di Angelantonio E, et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet. 2011;377(9771):1085–95. https://doi.org/10.1016/S0140-6736(11)60105-0.CrossRefPubMed

Danaei G. Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1·8 million participants. Lancet. 2014;383(9921):970–83.CrossRefPubMed

Perk J, De Backer G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J. 2012;33:1635–701.

Yudkin JS. Inflammation, obesity, and the metabolic syndrome. In: Hormone and metabolic research [internet]; 2007. p. 707–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17952830.

Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367(14):1310–20.CrossRef

10.

Széplaki G, Prohászka Z, Duba J, et al. Association of high serum concentration of the third component of complement (C3) with pre-existing severe coronary artery disease and new vascular events in women. Atherosclerosis. 2004;177:383–9.CrossRefPubMed

11.

Hertle E, Stehouwer CDA, van Greevenbroek MMJ. The complement system in human cardiometabolic disease. Mol Immunol. 2014 Oct;61(2):135–48.CrossRefPubMed

12.

Gupta NK, de Lemos JA, Ayers CR, et al. The relationship between C-reactive protein and atherosclerosis differs on the basis of body mass index. J Am Coll Cardiol. 2012;60(13):1148–55. Available from: http://linkinghub.elsevier.com/retrieve/pii/S073510971202342X CrossRefPubMed

13.

Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282(22):2131–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10591334 CrossRefPubMed

14.

Drapeau V, Lemieux I, Richard D, et al. Metabolic profile in severely obese women is less deteriorated than expected when compared to moderately obese women. Obes Surg. 2006;16(4):501–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16608618 CrossRefPubMed

15.

Shamai L, Lurix E, Shen M, et al. Association of body mass index and lipid profiles: evaluation of a broad spectrum of body mass index patients including the morbidly obese. Obes Surg. 2011;21(1):42–7. Available from: http://link.springer.com/10.1007/s11695-010-0170-7 CrossRefPubMed

16.

Bovenberg S A, Klop B, Alipour A, Martinez-Hervas S, Westzaan A, van de Geijn G-JM, et al. Erythrocyte-associated apolipoprotein B and its relationship with clinical and subclinical atherosclerosis. Eur J Clin Invest [Internet]. 2012 Apr [cited 2015 Jan 13];42(4):365–70. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21913916 CrossRefPubMed

17.

Klop B, van de Geijn G-JM, Bovenberg S a, van der Meulen N, Elte JWF, Birnie E, et al. Erythrocyte-bound apolipoprotein B in relation to atherosclerosis, serum lipids and ABO blood group. PLoS One. 2013 Jan [cited 2015 Jan 13];8(9):e75573. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3777967&tool=pmcentrez&rendertype=abstract

18.

Van Der Vorst JR, van Dam RM, van Stiphout RSA, et al. Virtual liver resection and volumetric analysis of the future liver remnant using open source image processing software. World J Surg. 2010;34(10):2426–33. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20652701 CrossRefPubMedPubMedCentral

19.

Eastwood SV, Tillin T, Wright A, et al. Estimation of CT-derived abdominal visceral and subcutaneous adipose tissue depots from anthropometry in Europeans, South Asians and African Caribbeans. PLoS One. 2013;8(9):e75085. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3775834&tool=pmcentrez&rendertype=abstract CrossRefPubMedPubMedCentral

20.

Zhang C, Rexrode KM, van Dam RM, et al. Abdominal obesity and the risk of all-cause, cardiovascular, and cancer mortality: sixteen years of follow-up in US women. Circulation. 2008;117(13):1658–67. Available from: http://circ.ahajournals.org/cgi/doi/10.1161/CIRCULATIONAHA.107.739714 CrossRefPubMed

21.

Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev. 2000;21(6):697–738. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11133069 CrossRefPubMed

22.

Hamer M, Stamatakis E. Metabolically healthy obesity and risk of all-cause and cardiovascular disease mortality. J Clin Endocrinol Metab [Internet]. 2012;97(7):2482–8. Available from: http://press.endocrine.org/doi/abs/10.1210/jc.2011-3475 CrossRef

23.

Virtue S, Vidal-Puig A. Adipose tissue expandability, lipotoxicity and the metabolic syndrome—an allostatic perspective. Biochim Biophys Acta Mol Cell Biol Lipids. 2010;1801(3):338–49. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1388198109002868 CrossRef

24.

Pellegrinelli V, Carobbio S, Vidal-Puig A. Adipose tissue plasticity: how fat depots respond differently to pathophysiological cues. Diabetologia. 2016;59(6):1075–88. Available from: http://link.springer.com/10.1007/s00125-016-3933-4 CrossRefPubMedPubMedCentral

25.

Kim J-Y, van de Wall E, Laplante M, et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Investig. 2007;117(9):2621–37. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17717599 CrossRefPubMed

26.

Onat A, Can G, Rezvani R, et al. Complement C3 and cleavage products in cardiometabolic risk. Clin Chim Acta. 2011;412(13–14):1171–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21419112 CrossRefPubMed

27.

Klop B, Cohn JS, van Oostrom AJHHM, et al. Daytime triglyceride variability in men and women with different levels of triglyceridemia. Clin Chim Acta. 2011;412(23–24):2183–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21864522 CrossRefPubMed

28.

Nordestgaard BG, Langsted A, Mora S, et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federa. Eur Heart J. 2016; Available from: http://www.ncbi.nlm.nih.gov/pubmed/27122601

29.

Porter SA, Massaro JM, Hoffmann U, et al. Abdominal subcutaneous adipose tissue: a protective fat depot? Diabetes Care. 2009;32(6):1068–75.CrossRefPubMedPubMedCentral

30.

Basterra-Gortari FJ, Beunza JJ, Bes-Rastrollo M, et al. Increasing trend in the prevalence of morbid obesity in Spain: from 1.8 to 6.1 per thousand in 14 years. Rev Esp Cardiol. 2011;64(5):424–6.CrossRefPubMed

31.

Khan SS, Ning H, Wilkins JT, et al. Association of body mass index with lifetime risk of cardiovascular disease and compression of morbidity. JAMA Cardiol. 2018;3(4):280. Available from: http://cardiology.jamanetwork.com/article.aspx?doi=10.1001/jamacardio.2018.0022 CrossRefPubMed

32.

Gerdts E, de Simone G, Lund BP, et al. Impact of overweight and obesity on cardiac benefit of antihypertensive treatment. Nutr Metab Cardiovasc Dis. 2013;23(2):122–9. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0939475311000883 CrossRefPubMed

33.

Dorresteijn JAN, Schrover IM, Visseren FLJ, Scheffer PG, Oey PL, Danser AH (Jan), et al. Differential effects of renin–angiotensin–aldosterone system inhibition, sympathoinhibition and diuretic therapy on endothelial function and blood pressure in obesity-related hypertension. J Hypertens. 2013;31(2):393–403. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00004872-201302000-00024

34.

Nicholls SJ, Tuzcu EM, Sipahi I, et al. Effects of obesity on lipid-lowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study). Am J Cardiol. 2006;97(11):1553–7. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0002914906003602 CrossRefPubMed

35.

Klenk J, Nagel G, Ulmer H, et al. Body mass index and mortality: results of a cohort of 184,697 adults in Austria. Eur J Epidemiol. 2009;24(2):83–91.CrossRefPubMed

36.

Eckel RH. Obesity and heart disease: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation. 1997;96(9):3248–50.CrossRefPubMed

37.

World Health Organization. Controlling the global obesity epidemic [Internet]. 2013 [cited 2016 Apr 12]. Available from: http://www.who.int/nutrition/topics/obesity/en/

38.

Dor A, Ferguson C, Langwith C, Tan E. A heavy burden: the individual costs of being overweight and obese in the United States. 2010.

Title: Discrepancies Between BMI and Classic Cardiovascular Risk Factors
Authors: Stefanie R. van Mil
Guy H. E. J. Vijgen
Astrid van Huisstede
Boudewijn Klop
Gert-Jan M. van de Geijn
Erwin Birnie
Gert-Jan Braunstahl
Guido H. H. Mannaerts
L. Ulas Biter
Manuel Castro Cabezas
Publication date: 01-11-2018
Publisher: Springer US
Published in: Obesity Surgery / Issue 11/2018
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI: https://doi.org/10.1007/s11695-018-3359-9

At a glance: The STEP trials

Springer Medicine

Discrepancies Between BMI and Classic Cardiovascular Risk Factors

Abstract

Background

Materials and Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Materials and Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2018

Destiny of Failed Adjustable Gastric Bandings: Do All the Patients Need Further Bariatric Surgery?

Update: 10 Years of Sleeve Gastrectomy—the First 103 Patients

Initial Assessment of Mucosal Capture and Leak Pressure After Gastrointestinal Stapling in a Porcine Model

Is Pre-operation Social Connectedness Associated with Weight Loss up to 2 Years Post Bariatric Surgery?

Laparoscopic Sleeve Gastrectomy Is Associated with Lower 30-Day Morbidity Versus Laparoscopic Gastric Bypass: an Analysis of the American College of Surgeons NSQIP

Letter to the Editor in Response to “Elipse Balloon: the Pitfalls of Excessive Simplicity” by Angrisani, L., Santonicola, A., Vitiello, A. et al. OBES SURG (2018) 28: 1419